<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01586767</url>
  </required_header>
  <id_info>
    <org_study_id>10-308</org_study_id>
    <secondary_id>2P01CA021239-29</secondary_id>
    <nct_id>NCT01586767</nct_id>
  </id_info>
  <brief_title>Intensity-Modulated or Proton Radiation Therapy for Sinonasal Malignancy</brief_title>
  <official_title>A Phase II Study of Intensity-Modulated or Proton Radiation Therapy for Locally Advanced Sinonasal Malignancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the hypothesis that 1)intensity-modulated radiotherapy
      (IMRT) or proton radiation therapy would result in improved local control rate and lowered
      toxicity compared to conventional radiotherapy, and 2) proton radiation therapy would result
      in equivalent or improved local control rate with similar or lower toxicity compared to IMRT,
      in the treatment of locally advanced sinonasal malignancy.

      Data from retrospective studies suggest that IMRT or proton radiation therapy resulted in
      promising outcome in patients with sinonasal malignancy. To this date, no prospective study
      has been conducted to evaluate the outcome of sinonasal cancer treated with IMRT or proton
      radiation therapy. This Phase II trial is the first prospective study conducted to determine
      the treatment outcome and toxicity of IMRT or proton in the treatment of sinonasal cancer.

      IMRT and proton radiation therapy are the two most established and most commonly employed
      advanced radiotherapy techniques for the treatment of sinonasal cancer. It is highly
      controversial whether one is superior to the other in terms of local control and toxicity
      outcome. It is also not clear if a subset of patients would benefit more from one treatment
      technology versus the other.

      Due to the rarity and heterogeneity of sinonasal malignancies and the fact that proton beam
      is only available at a few centers in the United States, it is not feasible at present to do
      a Phase III study randomizing patients between IMRT and proton radiation therapy. In this
      study, a planned secondary analysis will be performed, comparing the treatment and toxicity
      outcome between IMRT and proton. The data on the IMRT and proton comparison from this trial
      will be used to design future multi-center prospective trials and to determine if randomized
      trial is necessary.

      In this study, the treatment technique employed for an individual case will not be determined
      by the treating physician(s), but rather by the most advanced technology available at the
      treating institution for the treatment of the sinonasal cancer. At the Massachusetts General
      Hospital (MGH), proton beam therapy will be used for patients who meet the eligibility
      criteria. For institutions where protons are not available or institutions where the proton
      planning systems have not been optimized, IMRT exclusively will be used for the treatment of
      sinonasal cancer. Patient and tumor characteristics are expected to be comparable between
      IMRT- and proton- institutions
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will receive daily proton radiation treatment as outpatients at the Francis H. Burr
      Proton Center at Massachusetts General Hospital. The subjects may also receive concurrent
      standard chemotherapy every week during their radiation therapy. This chemotherapy is
      considered standard treatment for their cancer and is not being done for research purposes.

      In addition to daily radiation treatments, subjects will have the following tests every week:
      review of side effects; physical exam, including weight, height, neurological exam and vital
      signs; and blood tests, only for those subjects also receiving chemotherapy.

      Subjects will be followed for 5 years after the completion of study treatment. The first
      follow-up visit will be 6-8 weeks after completion of study treatment. Additional follow-up
      visits will be performed every 3 months during the first 2 years following completion of
      radiation then every 6 month during years 3-5. At each follow-up visit, subjects will receive
      a physical exam, chest CT scan (at 1st follow-up visit then at least every 6 months), a CT or
      MRI tumor assessment (at 1st follow-up visit then at least every 6 months), quality-of-life
      questionnaire, hearing test, neuro-ophthalmology test, and neurocognitive test.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local Control Rates</measure>
    <time_frame>2 years</time_frame>
    <description>To determine the local control rates with IMRT or proton radiation therapy at 2 years.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vision preservation</measure>
    <time_frame>5 years</time_frame>
    <description>To determine the late visual-orbital late effects of IMRT or proton beam</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Regional control</measure>
    <time_frame>2 years</time_frame>
    <description>To determine the regional control at 2 years after IMRT or proton</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>5 years</time_frame>
    <description>To determine the long-term survival at 5 years after IMRT or proton</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QOL</measure>
    <time_frame>5 years</time_frame>
    <description>To assess quality-of-life (QOL) outcomes after IMRT or proton</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patterns of Tumor Relapse</measure>
    <time_frame>5 years</time_frame>
    <description>To determine the patterns of tumor relapse after IMRT or proton</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local control</measure>
    <time_frame>5 years</time_frame>
    <description>To determine long-term local control after IMRT or proton</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive function</measure>
    <time_frame>5 years</time_frame>
    <description>To determine long-term neurocognitive function after IMRT or proton</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Adenoid Cystic Carcinoma</condition>
  <condition>Squamous Cell Carcinoma</condition>
  <condition>Sinonasal Carcinoma</condition>
  <condition>Sinonasal Undifferentiated Carcinoma</condition>
  <condition>Mucoepidermoid Carcinoma</condition>
  <condition>Schneiderian Carcinoma</condition>
  <condition>Myoepithelial Carcinoma</condition>
  <condition>Esthesioneuroblastoma</condition>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Proton beam therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects treated at Massachusetts General Hospital with proton beam therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IMRT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intensity-modulated radiation therapy at institutions other than Massachusetts General Hospital</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Proton radiation therapy</intervention_name>
    <description>Daily proton radiation therapy</description>
    <arm_group_label>Proton beam therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Intensity-modulated radiotherapy</intervention_name>
    <description>Daily intensity-modulated radiotherapy</description>
    <arm_group_label>IMRT</arm_group_label>
    <other_name>IMRT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Biopsy proven, within 16 weeks prior to study entry, sinonasal adenoid cystic
             carcinoma, adenocarcinoma, mucoepidermoid carcinoma, squamous cell carcinoma,
             including sinonasal carcinoma, sinonasal undifferentiated carcinoma, Schneiderian
             carcinoma, myoepithelial carcinoma, undifferentiated carcinoma, esthesioneuroblastoma,
             or melanoma AJCC 7th edition Stage III - IVA/B tumors, or with skull base or
             intracranial extension. Pathology must be confirmed by review at the treating
             institution.

          -  Patients with biopsy proven locally advanced sinus, nasal cavity, hard palate, soft
             palate, major or minor salivary gland tumors, or lacrimal apparatus, with nasal
             cavity, sinus, auditory canal, or skull base involvement are eligible.

          -  Eastern cooperative oncology group (ECOG) performance status 0 - 1 or Karnofsky
             Performance Status â‰¥ 70. (Appendix B)

          -  All patients must undergo pre-treatment evaluation of tumor extent prior to study
             entry through imaging studies and clinical examinations, including CT and/or MRI of
             skull base, brain and neck within 28 days prior to study entry; physical examination
             +/- nasal endoscopy within 28 days prior to study entry; and CT of the chest within 60
             days prior to study entry.

          -  Nutritional and general physical condition must be considered compatible with the
             proposed radiation +/- chemotherapy treatment.

          -  Normal organ and marrow function

        Exclusion Criteria:

          -  Active alcohol addiction

          -  Pregnant or breastfeeding

          -  Receiving any other study agents

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to cisplatin for subjects who will receive chemotherapy

          -  Evidence of distant metastases or distant leptomeningeal metastases

          -  Previous irradiation for head and neck tumor, skull base, or brain tumors

          -  Uncontrolled intercurrent illness

          -  History of a different malignancy unless disease-free for at least 2 years and are
             deemed by the investigator to be at low-risk for recurrence. Individuals with the
             following cancers are eligible if diagnosed and treated for cure within the past 2
             years: cervical cancer in situ, carcinoma in situ of the breast, and basal cell or
             squamous ceel carcinoma of the skin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Annie W Chan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2011</study_first_submitted>
  <study_first_submitted_qc>April 25, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2012</study_first_posted>
  <last_update_submitted>February 13, 2018</last_update_submitted>
  <last_update_submitted_qc>February 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Annie W. Chan, MD</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Nasal cavity</keyword>
  <keyword>Salivary gland tumors</keyword>
  <keyword>Hard palate</keyword>
  <keyword>Sinus</keyword>
  <keyword>Soft Palate</keyword>
  <keyword>Lacrimal Apparatus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Carcinoma, Adenoid Cystic</mesh_term>
    <mesh_term>Carcinoma, Mucoepidermoid</mesh_term>
    <mesh_term>Esthesioneuroblastoma, Olfactory</mesh_term>
    <mesh_term>Maxillary Sinus Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

